Concepedia

Claudia Merz

CM

8

Publications

495

Citations

8

H-Index

2008

Active since

Affiliations

Bayer (Germany)(Current)

Dana-Farber Cancer Institute

Hospital Universitario Fundación Jiménez Díaz

Bayer (United States)

University of Colorado Denver

Claudia Merz is an author at Bayer (Germany) specializing in tumor biology, cancer research, and pathology.

ORCID

Top concepts

Publications per year

2008–2022

8

Publications

8

The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies

Sven Christian, Claudia Merz, Laura Evans et al. · Leukemia · 2019 · 232 citations · Full text

, , +17

Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance

Maria Quanz, Eckhard Bender, Charlotte Kopitz et al. · Molecular Cancer Therapeutics · 2018 · 106 citations · Full text

First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy

Jennifer R. Diamond, Valentina Boni, Emerson A. Lim et al. · Clinical Cancer Research · 2022 · 52 citations · Full text

Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases

Arne von Bonin, Alexandra Rausch, Anne Mengel et al. · Experimental Dermatology · 2010 · 44 citations

Safety and efficacy of VIP152, a CDK9 inhibitor, in patients with double-hit lymphoma (DHL).

Vı́ctor Moreno, Raúl Córdoba, Daniel Morillo et al. · Journal of Clinical Oncology · 2021 · 21 citations

Rows per page

1–5 of 8